TransCode Therapeutics reports 2022 operating loss of $17.9M; cash runway into Q2 2023

Transcode Therapeutics, Inc.

2023-Q1 EPS reported -$0.33

Cash at Dec 31, 2022: $5.0M, down from $20.8M at Dec 31, 2021.
Operating loss of $17.9M in 2022 vs $6.8M in 2021; R&D expense $10.5M (up from $2.8M).
Cash of $5.0M plus $1.3M from Feb 2023 offering and $871k SBIR expected to fund into but not through Q2 2023.
FDA authorized Phase 0 FIH trial for lead candidate TTX-MC138 in advanced solid tumors.
Strategic alliance with MD Anderson and Orphan Drug Designation for TTX-siPDL1 in pancreatic cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Transcode Therapeutics, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

TransCode Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-040152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.